Objective: Recently, mechanical thrombolytic therapy has been introduced as an alternative or adjunct to pharmaceutical thrombolytic therapy in removing thrombus from vascular system. Recurrent thrombosis has been a challenge for thrombolytic therapies. We hypothesize that soluble clotting factors released during a mechanical thrombectomy procedure may be responsible for creating a localized hypercoagulable state and could be one of the underlying causes of recurrent thrombosis. Method: Blood samples were obtained from 20 participants with no history of hypertension, vascular disease, and antiplatelet/ anticoagulation therapy. For each whole blood (WB) sample, we measured activated clotting time (ACT) and clotting rate (CR) at the baseline and then with added agitated and nonagitated clot serums. The same set of measurements was performed on platelet-rich plasma (PRP) samples of each participant. We tested for changes in coagulation profile between baseline samples and those with added supernatant serums obtained from autologous blood clot. Result: We observed a significant decrease in ACT for WB with agitated and nonagitated clot serums (49%, P <.0001 and 25%, P =.01, respectively) compared to the baseline WB. The same trend was observed for PRP samples with agitated and nonagitated clot serums (28%, P =.002 and 18%, P =.05, respectively). The CR was increased (a steeper slope) by 83% for samples with added agitated clot serum only (P =.007). Conclusion: We observed a significant change for ACT in WB samples with added clot serums as compared to the baseline WB samples. The results of this study suggest that the soluble substances released from clotting blood have profound procoagulant effects.
- blood coagulation factors